Nanoparticles restore light response in blind mice, study finds

September 24, 2026 at 11:56 AM1 min

This digest was compiled by AI from multiple sources — links to the originals are below.

An international team led by Aarhus University developed light-sensitive nanoparticles that, when injected into the eye, activate surviving retinal neurons in blind mice. The particles, about 300 nanometers in diameter, triggered responses in the visual cortex and behavioral reactions to light. The findings were published in Nature Biomedical Engineering.

Key Facts

The nanoparticles are approximately 300 nanometers in diameter and made of graphitic carbon nitride, a semiconductor material.
In experiments on fully blind mice, the nanoparticles elicited responses in the visual cortex and behavioral reactions to light.
The technology was also successfully tested on isolated pig retinal tissue.
The study was published in Nature Biomedical Engineering.

Nanoparticle Design

The nanoparticles are hollow spheres about 300 nanometers in diameter, composed of graphitic carbon nitride, a semiconductor material. Their structure resembles plant chloroplasts and maximizes absorption of visible light. After injection, the particles settle evenly on the retinal surface near neurons. When light hits the nanoparticles, they trigger local physicochemical reactions that generate an impulse, prompting nearby nerve cells to send signals to the brain.

Experimental Results

In fully blind mice, researchers recorded responses in the visual cortex when light was turned on. The animals also began to react behaviorally to changes in illumination. The system's effectiveness was confirmed on isolated pig retinal tissue. The approach bypasses dead photoreceptors by directly stimulating surviving ganglion neurons that send visual signals to the brain.

Advantages and Next Steps

Unlike gene therapy tailored to specific pathologies or electronic chips requiring invasive surgery, the nanoparticles are delivered by a simple injection and work regardless of the cause of vision loss. The authors plan to study the long-term safety of the material in eye tissues before starting human clinical trials.